Compass Pathways plc (Nasdaq: CMPS), a biotechnology company focusing on mental health innovations, reported its financial results for the second quarter of 2025. The company achieved a positive primary endpoint in its first COMP360 Phase 3 trial, demonstrating a statistically significant and clinically meaningful reduction in depression at six weeks without unexpected safety findings. The second pivotal Phase 3 trial continues enrolling, with results expected in the second half of 2026. For the six months ended June 30, 2025, Compass Pathways reported a net loss of $56.3 million, or a loss of $0.62 per share, compared to a net loss of $73.3 million, or a loss of $1.11 per share, during the same period in 2024. This decrease in net loss was primarily due to a $16.9 million non-cash gain on fair value adjustment related to warrant liabilities. Research and development expenses rose to $61.2 million from $54.0 million in the same period in 2024, mainly due to expenses related to advancing late-stage COMP360 Phase 3 clinical trials. General and administrative expenses were reduced to $12.6 million from $14.3 million, influenced by decreased staffing levels following a reorganization in the fourth quarter of 2024. The company ended the quarter with $221.9 million in cash and cash equivalents, up from $165.1 million at the end of 2024, and maintains a cash runway into 2027. Compass Pathways is considering options for a potential accelerated filing of COMP360 for treatment-resistant depression. The company expects net cash used in operating activities for the full year 2025 to be between $120 million and $145 million.